Navigation Links
InterMune to Present at Citi's 4th Annual Biotech Day
Date:3/30/2009

BRISBANE, Calif., March 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Citi's 4th Annual Biotech Day in New York City on April 1, 2009 at 10:40 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY, and a research program focused on pirfenidone analog ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
2. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
3. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
4. InterMune Announces Issuance of U.S. Patent for ITMN-191
5. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
6. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
7. InterMune to Present at J.P. Morgan Healthcare Conference
8. InterMune to Present at Deutsche Bank Biotech Boston Confab
9. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
10. InterMune to Release Third Quarter 2008 Financial Results on November 6
11. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
(Date:3/18/2016)... --> --> ... & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection ... border security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, ... defence & security companies in the border security ...
Breaking Biology News(10 mins):